Loxo eyeing larotrectinib registration

Loxo Oncology Inc. (NASDAQ:LOXO) gained $6.95 (26%) to $33.86 after it disclosed a submission timeline for larotrectinib (LOXO-101) and reported new data from a Phase I study

Read the full 279 word article

User Sign In